Projected Cost‐Effectiveness of Rotavirus Vaccination for Children in Asia

Podewils, Laura Jean; Antil, Lynn; Hummelman, Erik; Bresee, Joseph S.; Parashar, Umesh D.; Rheingans, Richard

doi:10.1086/431513

Cited by 103 publications

(86 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our estimate of 7.8 per 1,000 children a year aged less than fi ve requiring hospitalisation for RV-AGE corresponds to a cumulative incidence of 38.7 per 1,000 children requiring hospitalisation by age fi ve. This is considerably higher than a recent US estimate (12.5 per 1,000), 10 but is comparable with a recent average estimate for Korea, Japan and Hong Kong (41.5 per 1,000) 11 and for China, Malaysia and Thailand (45.9 per 1,000), 11 and is considerably lower than a recent estimate for Argentina (83 per 1,000). 12 The reason for the low hospitalisation rate estimate for the US may be due in part to an overly conservative methodology (the residual method, which assumes that no hospital cases in the off-season are attributable to rotavirus).…”

Section: General Practitioner (Gp) Visitssupporting

confidence: 53%

The burden of rotavirus‐related illness among young children on the Australian health care system

Galati

Harsley

Richmond

et al. 2006

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

R otavirus (RV) is a major cause of acute gastroenteritis (AGE) in children under the age of fi ve and is a signifi cant cause of early childhood mortality in developing countries and morbidity in developed countries.1 Estimates for Australia from the mid 1990s put the direct national healthcare burden of RV at 10,000 hospital admissions 2 and 50,000 primary care visits 3 annually. These estimates were compiled to provide primary data for a cost-effectiveness analysis of RV vaccination in Australia. 3The previous cost-effectiveness analysis was framed around the vaccine Rotashield, which was licensed in the United States in 1998 but was voluntarily withdrawn from the market by its manufacturer a short time later after surveillance revealed an increased incidence of intussusception in infants who had been immunised. 4 Since then, several new RV vaccines have been under development and two were approved for use in Australia in 2006.5 In this context, this paper presents updated epidemiological data on numbers and costs of hospitalisations of young children in Australia for AGE and on the fraction of these hospitalisations that are attributable to RV (the 'RV fraction'). Estimates of numbers and costs of emergency department (ED) visits and numbers of general practitioner (GP) visits in Australia for RV-AGE are also included. A new method for estimating the RV fraction on the basis of the seasonal pattern of incidence is used.

show abstract

Section: General Practitioner (Gp) Visitssupporting

confidence: 53%

The burden of rotavirus‐related illness among young children on the Australian health care system

Galati

Harsley

Richmond

et al. 2006

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

show abstract

“…It is obvious that the direct costs of diarrhea vary according to country's level of development and the type of health system it applies. For example, in Asia the medical costs of diarrhea are different for low income ($29 million), middle ($114 million) and high income countries ($46 million) [15].…”

Section: Discussionmentioning

confidence: 99%

“…As suggested in the literature, rotavirus is a very common cause of severe diarrhea and hospitalization for children under age of five in developed [12,14,16] and developing countries [4]. Numerous studies have shown that rotavirus immunization programs might be cost-effective, even though many aspects have to be taken into consideration such as morbidity and mortality rates due to rotavirus and vaccine price [7,12,13,15]. Besides the actual costs of diarrhea, these very important aspects related to rotavirus immunization should be investigated through carefully designed future studies, in order to help the decision makers to opt for a vaccination program or other potential interventions.…”

Section: Discussionmentioning

confidence: 99%

Diarrhea Associated Costs among Children Less Than 5 Years of Age from Health Care Provider and Social Perspectives in Albania

Ahmeti

Simaku

Preza

et al. 2013

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…Confusion between I$ from Goldie et al, 2007(Goldie et al, 2007 and US$ (I$ higher than US$ 7.3 Rotavirus Since the rotavirus vaccine can be administered at the same time as the current recommended tetravalent DTPw-Hib and OPV vaccines, incremental administration costs were assumed to be low. Both administration costs (US$1, in BRL2004, exchange rate: US$1 = BRL2.65, Brazilian Central Bank) and expected losses from waste (10% of vaccine doses) were taken from the literature, as no local data were available (Podewils et al, 2005;192 (suppl 1):S133-45.) (Podewils et al, 2005) De Soárez et al 2008 (de Soarez et al, 2008) 4.96 …”

Section: 3mentioning

confidence: 99%

“…Both administration costs (US$1, in BRL2004, exchange rate: US$1 = BRL2.65, Brazilian Central Bank) and expected losses from waste (10% of vaccine doses) were taken from the literature, as no local data were available (Podewils et al, 2005;192 (suppl 1):S133-45.) (Podewils et al, 2005) De Soárez et al 2008 (de Soarez et al, 2008) 4.96 …”

Section: 3mentioning

confidence: 99%

Cost-effectiveness of dengue vaccination in Brazil

Durand

Genovez

Araújo

2017

JBES

View full text Add to dashboard Cite

Objective: To define the economic value of a tetravalent dengue vaccine in Brazil by estimating the cost-effectiveness vaccine price threshold per dose. Methods: A dengue dynamic transmission model was used to estimate the public health impact of dengue vaccination and related economic parameters. Two vaccination strategies were assessed: routine vaccination at 9 years old plus either a catch-up campaign of 7 cohorts (10 to 16 years old; R9&10-16) or 16 cohorts (10 to 25 years old; R9&10-25). Brazilian-specific demographic, epidemiological and economic data were used. The economic impact over 10 years was estimated from the public payer and societal perspectives. All costs were expressed in BRL2016. Results: Over 10 years, the R9&10-16 and R9&10-25 vaccination strategies would prevent 9 million and 15 million dengue cases, respectively, avoiding 269,906 (95% CI: 410,097-154,653) and 434,334 (95% CI: 547,052-304,799) disability-adjusted life years. This would result in savings of up to BRL7.4 billion (US$2.1 billion) from a societal perspective with the larger vaccination program. The cost-effective vaccine price threshold per dose for the R9&10-16 and R9&10-25 strategies would be BRL187.5 (95% CI: 109-276) (US$52.1) and BRL183.6 (95% CI: 129-230) (US$51.0), respectively, from the public payer perspective, and BRL221.5 (95% CI: 129-326) (US$61.5) and BRL216.8 (95% CI: 153-271) (US$60.2), respectively, from the societal perspective. Conclusion:The high threshold of vaccine price per dose demonstrates the significant economic value of dengue vaccination in Brazil, even for a large program with 16 catch-up cohorts. RESUMOObjetivo: Definir o valor econômico da vacina tetravalente contra dengue no Brasil por meio da estimativa do limiar de preço custo-efetivo por dose. Métodos: Um modelo dinâmico de transmissão foi utilizado para estimar o impacto em saúde pública da vacinação contra dengue e os parâ-metros econômicos relacionados. A análise avaliou duas estratégias de vacinação: rotina aos 9 anos, mais campanha de vacinação com 7 coortes (10 a 16 anos; R9&10-16) ou 16 coortes (10 a 25 anos; R9&10-25). Foram utilizados dados demográficos, epidemiológicos e econômicos específicos para o Brasil. O impacto econômico foi estimado em 10 anos sob a perspectiva do pagador público e da sociedade. Todos os custos foram expressos em BRL2016. Resultados: Em 10 anos, as estratégias de vacinação R9&10-16 e R9&10-25 preveniriam 9 milhões e 15 milhões de casos de dengue, respectivamente, evitando 269,906 (95% CI: 410,097-154,653) e 434,334 (95% CI: 547,052-304,799) anos de vida ajustados por incapacidade. Isso resultaria em uma economia de até BRL7,4 bilhões (US$2,1 bilhões) sob a perspectiva da sociedade com o maior programa de vacinação. O limiar de preço custo-efetivo por dose para as estratégias R9&10-16 e R9&10-25 seria BRL187,5 (95% CI: 109-276) (US$52,1) e BRL183,6 (95% CI: 129-230) (US$51,0), respectivamente, sob a perspectiva do público pagador, e BRL221,5 (95% CI: 129-326) (US$61,5) e BRL216,8 (95% CI: 153-271) (US...

show abstract

Projected Cost‐Effectiveness of Rotavirus Vaccination for Children in Asia

Cited by 103 publications

References 35 publications

The burden of rotavirus‐related illness among young children on the Australian health care system

The burden of rotavirus‐related illness among young children on the Australian health care system

Diarrhea Associated Costs among Children Less Than 5 Years of Age from Health Care Provider and Social Perspectives in Albania

Cost-effectiveness of dengue vaccination in Brazil

Contact Info

Product

Resources

About